Current Oncology (Aug 2021)

Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience

  • Maria Camila Quinones,
  • Karl Bélanger,
  • Émilie Lemieux Blanchard,
  • Bernard Lemieux,
  • Jean-Paul Bahary,
  • Laura G. Masucci,
  • David Roberge,
  • Cynthia Menard,
  • Carole Lambert,
  • France Berthelet,
  • Robert Moumdjian,
  • Marie Florescu

DOI
https://doi.org/10.3390/curroncol28040271
Journal volume & issue
Vol. 28, no. 4
pp. 3104 – 3114

Abstract

Read online

Medulloblastoma is an aggressive primary brain tumor that is extremely rare in adults; therefore, prospective studies are limited. We reviewed the information of all MB patients treated at the CHUM between 2006 and 2017. We divided our cohort by age and further divided adult patients (53%) in two groups, those diagnosed between 2006–2012 and 2013–2017. In our adult population, median follow up was 26 months and SHH-activated MB comprised 39% of tumors. Adult 5yOS was 80% and first-line therapy led to a 5yPFS of 77%. The absence of radiosensitizing chemotherapy (100% vs. 50%; p = 0.033) negatively influenced 5yPFS. 96% of adult patients received radiotherapy and 48% of them received concomitant radiosensitizing chemotherapy. Complete surgical resection was performed on 85% of adults, but the extent of resection did not have a discernable impact on survival and did not change with time. Adjuvant chemotherapy did not clearly affect prognosis (5yOS 80% vs. 67%, p = 0.155; 5yPFS 78% vs. 67%, p = 0.114). From 2006–2012, the most common chemotherapy regimen (69%) was Cisplatinum, Lomustine and Vincristine, which was replaced in 2013 by Cisplatinum, Etoposide and Cyclophosphamide (77%) with a trend for worse survival. Nine patients recurred and seven of these (78%) were treated with palliative chemotherapy. In conclusion, we did not identify prognostic demographic or tumor factors in our adult MB population. The presence of radiosensitizing chemotherapy was associated with a more favorable PFS. Cisplatinum, Lomustine and Vincristine regimen might be a better adjuvant chemotherapy regimen.

Keywords